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Anticancer RuII and RhIII Piano-Stool Complexes that are
Histone Deacetylase Inhibitors
Jasmine M. Cross,[a] Tim R. Blower,[b] Natalie Gallagher,[c] Jason H. Gill,[c] Kimberly L. Rockley,[c]
and James W. Walton*[a]
The first examples of RuII and RhIII piano-stool complex histone
deacetylase (HDAC) inhibitors are presented. The novel com-
plexes have antiproliferative activity against H460 non-small-
cell lung carcinoma cells that is comparable to the clinically
used HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).
Strong evidence for HDAC inhibition as a primary mechanism
of action is provided. The complexes reported here represent
an important step towards the design of highly active and se-
lective HDAC inhibitors.
Historically the treatment of advanced or disseminated cancer
has involved the systemic administration of cytotoxic com-
pounds targeting nucleic acid replication or synthesis, many of
which have been approved for clinical use since the 1960s.[1]
Mechanistically these agents do not exclusively target cancer
cells, and will also attack any rapidly proliferating cell type,
commonly resulting in dose-limiting toxicity.[2] Over the past
decade, increased understanding of the molecular basis of
cancer has advanced cancer therapy into an era of “targeted
molecular therapeutics”.[3] This new class of targeted drugs ex-
hibit a broad range of therapeutic mechanisms, including in-
hibition of extracellular growth receptors,[4] activation of cell
death pathways,[5] retardation of cell motility,[6] kinase inhibi-
tion,[7] and toxin delivery,[8] to name a few. Subsequently, inhib-
ition of enzymes associated with key regulatory pathways in
cancer is an attractive alternative to targeting DNA.[9] In princi-
ple, “molecularly targeted” agents are highly selective agents
against the growth and survival of tumour cells, whilst sparing
normal cells.
The histone deacetylases (HDACs) are a class of enzymes re-
cently shown to be suitable molecular targets for anticancer
activity.[10] HDACs, working in tandem with histone acetylase
transferases, control the extent of acetylation of e-lysine resi-
dues in the tail of histone proteins[11] and several other cellular
proteins, such as tubulin.[12] In terms of histones, deacetylation
leads to a positively charged histone core, which interacts
strongly with DNA, leading to a condensed chromatin struc-
ture. As a consequence, transcription of tumour-suppressor
genes is repressed and cancer cell survival is promoted.[13] Con-
sequently, HDAC inhibitors have received much attention as
drug candidates, with suberoylanilide hydroxamic acid (SAHA,
Figure 1) approved for clinical use against cutaneous T-cell
lymphoma.[14] The hydroxamic acid group in SAHA binds to
a Zn2+ ion located at the bottom of a hydrophobic cavity in
the active site of HDAC enzymes.
It is known that the HDAC protein family is comprised of
several sub-families demonstrating a wide range of roles
across the cell, in addition to modulation of histone-regulated
gene transcription.[15] Therefore there is significant interest in
the development of HDAC inhibitors with the capability of se-
lectively targeting a specific enzyme or sub-family,[16] with the
objective of avoiding HDACs involved in normal physiological
function and drug-induced toxicities.
Figure 1. The HDAC inhibitor SAHA and the piano-stool complexes featured
in this study. Cp*=pentamethylcyclopentadienyl.
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In terms of selectivity, although the enzymatic cavity is rela-
tively comparable between HDACs, there is clear variability in
the protein structure towards the entrance of the cavity. The
phenyl headgroup of enzyme-bound SAHA sits in this region
and offers scope for modification toward the development of
HDAC-selective agents or more potent drugs through greater
chemical affinity. In recent years, HDAC inhibitors have been
developed in which the phenyl headgroup is replaced or func-
tionalised with a metal complex. Examples include ferroce-
ne-,[17] platinum-,[18] rhenium-[19] and ferrocifen-based[20] inhibi-
tors. In each case the pharmacological effects are retained and,
in some cases, improved cytotoxicity relative to SAHA was ob-
served. Luminescent octahedral polypyridyl–metal complexes
have also been developed.[21] The advantages of metal com-
plexes over purely organic compounds in enzyme inhibition in-
clude: 3D metal geometries, allowing simultaneous access to
multiple areas of the active site; exchangeable ligands, for
in situ activation and potential binding to amino acid residues
in the active site; simple and modular syntheses, allowing
rapid determination of structure–activity relationships.
To be a successful selective headgroup, the metal complex
would ideally have scope and functionality amenable to modi-
fication for optimising the interactions with the cavity en-
trance. One such class of metal-based compounds demonstrat-
ing these characteristics is the piano-stool complexes, compris-
ing a d6 low-spin metal core capped by a h6 or h5 aromatic
ligand. Functionality is varied at the three remaining coordina-
tion sites of the pseudo-octahedral complexes, which are occu-
pied by mono-, bi- or tri-dentate ligands. A large number of
metal complexes based on this motif have been investigated
for their anticancer activity,[22] with modification of each com-
ponent leading to dramatic changes in activity. However, RuII
and RhIII piano-stool complexes have not previously been in-
vestigated as HDAC inhibitors.
Herein, we present the first examples of RuII and RhIII piano-
stool complexes that show effective HDAC inhibition and anti-
proliferative activity against H460 non-small-cell lung carcino-
ma cells. Our initial biological studies indicate that these com-
plexes inhibit class I and II HDAC enzymes, but show no cova-
lent binding to DNA.
We chose to use a substituted phenanthroline moiety, as
this ligand is known to form stable chelates with the platinum
group metals.[22i, 23] Following a literature procedure,[21a] 1,10-
phenanthrolin-5-amine and methyl 8-chloro-8-oxooctanoate
were reacted to give a methyl ester intermediate. Without fur-
ther purification, this intermediate was converted to ligand L1
by the addition of hydroxylamine (50% aqueous solution) and
catalytic base (Scheme 1). Upon neutralisation, L1 precipitated
and was collected by filtration and dried under high vacuum.
Complexation of L1 with selected metal dimers ([(arene)MCl2]2)
was achieved using a 2:1 ratio of L1/metal dimer in anhydrous
methanol. After removing the excess solvent, the crude prod-
uct was purified by recrystallisation by dropping a concentrated
CH2Cl2 solution into stirred Et2O in a dry-ice/acetone bath
(Scheme 1). Formation and purity of the complexes was con-
firmed using 1H NMR spectroscopy, mass spectrometry and ele-
mental analysis (see the Supporting Information for details).
1H NMR spectroscopy in [D6]DMSO confirmed the presence of
the intact hydroxamic acid, with broad resonances at 10.30
and 8.63 ppm corresponding to the hydroxamic acid OH and
NH protons of complex 1, respectively (10.38 and 8.63 ppm for
complex 2). These resonances are near identical to those of L1,
confirming that chelation to Ru occurs only through the phe-
nanthroline N donors. In contrast, the resonances for protons
H2 and H9, adjacent to the phenanthroline N atoms, shift by
almost 1 ppm upon complexation.
To assess the aqueous stability of the complexes, a solution
of complex 1 in D2O was monitored by
1H NMR spectroscopy
over the course of 96 h. After 1 h, an equilibrium was estab-
lished between the chlorido complex 1 and the aqua species,
in which the chlorido ligand has exchanged with D2O. The
chlorido/D2O ratio is approximately 9:1 and remains un-
changed over the course of 96 h (see the Supporting Informa-
tion for full details). These results show that the complex is
stable in aqueous solution and likely to remain intact as the
chlorido species in biological media.
With the new complexes in hand, we first examined their
ability to inhibit the proliferation of the H460 non-small-cell
lung carcinoma cell line in vitro. Cells were exposed for 96 h to
each new complex, the ligand L1 and the known HDAC inhibi-
tor, SAHA, at concentrations ranging from 0.01 to 200 mm. Cell
survival was then determined by the MTT assay[24] and the IC50
(concentration of compound required to inhibit cell prolifera-
tion by 50%) was calculated from the resulting dose–response
curve (see the Supporting Information for full details). The re-
sults (Table 1) show that the new complexes are able to effec-
tively inhibit cell growth. The RuII complex with the capping p-
cymene ligand (complex 1) has an IC50 value of approximately
20 mm, which is comparable to that found in cytotoxicity stud-
ies of many other Ru piano-stool complexes,[22] but is 15-fold
higher than for SAHA. However, the much lower cytotoxic effi-
cacy (IC50 : 4 mm) demonstrated by the Rh
III complex, capped
with a Cp* ligand (complex 2) is comparable with the most
active RhIII piano-stool complexes reported to date.[25] The
lower IC50 value of complex 2 and the fact it is approaching
that of the clinically approved anticancer agent, SAHA (IC50 :
Scheme 1. Preparation of piano-stool complexes of RuII (1) and RhIII (2).
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1.4 mm), gives us encouragement that piano-stool complexes
have the potential to act as HDAC inhibitors. Within experi-
mental error the ligand L1 has the same activity as SAHA.
To investigate whether these complexes act by HDAC inhibi-
tion, as proposed, we carried out enzyme inhibition assays,
using a commercially available assay kit.[26] Fluorescence meas-
urements were used to determine the extent of HDAC activity,
with no fluorescence indicating complete HDAC inhibition. The
known inhibitor SAHA, L1 and each new complex were incu-
bated at 0.1 and 1 mm with a nuclear extract source of HDACs,
prior to the addition of an acetylated substrate. As a positive
control, the assay was also run in the absence of any inhibitor.
Results are presented as a percentage of HDAC activity, relative
to the positive control (Table 2). For all compounds tested at
1 mm concentration, HDAC activity is low (<5% activity), show-
ing that these species are effective HDAC inhibitors. At 0.1 mm,
HDAC activity is increased, but remains low, supportive of the
inhibitory potency of these compounds. Although all tested
compounds inhibit HDAC activity to the same order of magni-
tude, the extent of HDAC inhibition at the lower concentration
follows the order SAHA>L1>2>1. This order mirrors the in
vitro anticancer activity, which supports the hypothesis that
HDAC inhibition is a putative mechanism of action of these
species. Beyond this empirical observation, there are some in-
teresting features within the results. Firstly, complex 2 showed
a fourfold greater cytotoxic potency than complex 1, but com-
parable HDAC inhibitory activity. This would suggest that the
lower anticancer activity of the RuII complex is not entirely
down to weaker HDAC inhibition. More likely, variation in pro-
cesses such as cell uptake, localisation and egress of the com-
pounds lead to the observed differences in cytotoxicity. A
second observation from the data is that, despite being more
active at 0.1 mm, at the higher concentration of 1 mm, the
ligand L1 leads to less enzyme inhibition than the complexes 1
and 2. This might be due to aggregation of the planar aromat-
ic L1 at higher concentration,[27] leading to a reduction in com-
pound available to bind to the enzyme, or might be due to
lower solubility in the assay medium.
As a control, we measured the extent of HDAC inhibition by
the known complex [(p-cymene)Ru(phen)Cl]Cl.[28] As expected,
this complex shows no significant inhibition (100% HDAC ac-
tivity at 1 mm complex), confirming that the hydroxamic acid
moiety is essential for HDAC inhibition.
The HDAC assays clearly indicate that the new complexes
are effective inhibitors of these enzymes. However, we wanted
to determine whether this was the only mechanism of action
that led to the observed cytotoxicity. Indeed, the majority of
anticancer RuII piano-stool complexes are postulated to act
through covalent binding to DNA. To test whether the com-
plexes investigated herein interact with DNA, either through
covalent modification or intercalation, DNA binding assays
were performed. Firstly, to probe the ability of the complexes
to covalently modify DNA, supercoiled pSG483 plasmid DNA
was exposed to increasing concentrations of complex 2 and
the resulting products were separated by agarose gel electro-
phoresis (Figure 2A). In comparison to a solvent only control
(Figure 2A, lane 1), the migration of the supercoiled DNA is un-
affected by complex 2. As a comparison, the known DNA-bind-
ing complex cisplatin was examined under identical conditions
(Figure 2B). As the concentration of cisplatin was increased,
the compound formed covalent adducts with DNA that migrat-
ed more slowly, reaching a maximal shift at 2.5 mm. Above this
concentration, the DNA signals became more disperse, likely
indicating degradation of the DNA at higher concentrations of
the compound. It is clear from this comparison that complex 2
does not covalently bind DNA.
Having confirmed that covalent binding to DNA is not fav-
oured for complex 2, we next explored the possibility of inter-
calation. Assays were run in which nicked pSG483 plasmid
DNA was incubated with potential intercalators, then treated
with DNA ligase (Figure 3). The ligase acts to re-seal the nicked
DNA, trapping the current supercoiling state of the plasmid. In-
Table 1. IC50 values measured using the MTT assay (96 h) against the
non-small-cell lung carcinoma H460 cell line, and are reported as the
mean value from at least three experiments.
Compound Arene–metal IC50 [mm]
1 p-cymene–RuII 21:6
2 Cp*–RhIII 4.1:0.4
L1 – 1.5:0.2
SAHA – 1.4:0.2
Table 2. HDAC activity in presence of potential inhibitors at 0.1 and 1 mm
concentration, measured using a commercially available assay kit. Values
are reported as percentage activity relative to a positive control (no inhib-
itor).
Inhibitor concn [mm] Control [%] SAHA [%] 1 [%] 2 [%] L1 [%]
1 100 0.5 1.6 1.1 4.9
0.1 100 6.3 17.3 15.4 10.7
Figure 2. Covalent modification of DNA as determined by migration of sub-
strate DNA during agarose gel electrophoresis. Supercoiled plasmid DNA
was treated with increasing concentrations of complex 2 (A) and cispla-
tin (B). SC= supercoiled DNA.
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tercalating compounds induce increased supercoiling within
plasmid DNA, whereas non-intercalated nicked DNA treated
with ligase will be sealed in a distribution of relaxed DNA top-
oisomers (Figure 3, lane 3). No intercalation was observed for
concentrations of complex 2 below 20 mm, indicating that in-
tercalation was not occurring at concentrations capable of
causing HDAC inhibition or cytotoxicity. At higher doses, 20–
80 mm of complex 2, moderate intercalation could be ob-
served. As a positive control, the known DNA intercalator acri-
dine orange was tested at 1.25 mm, producing supercoiled
DNA and demonstrating that in comparison, complex 2 does
not intercalate DNA (Figure 3, lane 13).
From the assays carried out to determine one or more
mechanism(s) of action, it is clear that HDAC inhibition is a po-
tential therapeutic mechanism of anticancer activity in vitro.
The results of our biological assays rule out covalent binding
to DNA in a manner akin to cisplatin or many other RuII piano-
stool complexes. Similarly, complex 2 does not intercalate with
DNA at efficacious concentrations, as might be expected from
a complex incorporating a planar aromatic ligand. Hence, we
can be confident that a viable mechanism of anticancer activity
of the new RuII and RhIII complexes is through HDAC inhibition.
In conclusion, we have presented the first examples of RuII
and RhIII piano-stool complexes that inhibit HDAC enzymes,
leading to growth inhibition of a lung carcinoma cell line.
These complexes have comparable activity to the clinically ap-
proved inhibitor SAHA. The key advantage to using 3D piano-
stool complexes for this application is the ease in which the
structure of the metal complex can be varied. For example, the
capping arene group or monodentate halide can be readily
modulated to form 3D structures that might access new areas
on the enzyme surface, leading to more efficient binding. This
so-called “escape from flatland”[29] is much harder to envisage
for the purely organic inhibitors, the synthesis of which would
require longer and more challenging pathways. We are cur-
rently using computational modelling to aid in the design of
more efficient piano-stool complex HDAC inhibitors.
Furthermore, whereas SAHA is a pan-HDAC inhibitor, the
design of inhibitors that are selective towards a particular iso-
form is at the forefront of research in this area.[16]
Piano-stool complexes, such as 2, provide a platform
from which selective HDAC inhibitors can be de-
signed and synthesised with comparative ease. The
use of selective inhibitors should provide more in-
sight into the physiological roles of the HDAC iso-
forms and might reveal undiscovered functions of
this important enzyme.
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